Israel-based generic drug maker Teva Pharmaceutical Industries Ltd. on Wednesday reported a loss for the fourth quarter that narrowed from last year as a decline in revenues was more than offset by lower costs and expenses. However, adjusted earnings per share missed analysts’ expectations, while revenues beat estimates. Teva provided its financial outlook for fiscal 2019 also below estimates.
RTT – Earnings
BEST DEAL UPDATE: